JP7837952B2 - ヘテロアリール基化合物、その製造方法および使用 - Google Patents

ヘテロアリール基化合物、その製造方法および使用

Info

Publication number
JP7837952B2
JP7837952B2 JP2023513401A JP2023513401A JP7837952B2 JP 7837952 B2 JP7837952 B2 JP 7837952B2 JP 2023513401 A JP2023513401 A JP 2023513401A JP 2023513401 A JP2023513401 A JP 2023513401A JP 7837952 B2 JP7837952 B2 JP 7837952B2
Authority
JP
Japan
Prior art keywords
group
formula
substituted
ring
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023513401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540228A5 (https=
JPWO2022042630A5 (https=
JP2023540228A (ja
Inventor
シン ダイ，
ホン ヤン，
シアンハイ ファン，
ハオタオ ニュウ，
ジシン ハン，
ジェンウ ワン，
チャン ツァン，
ヤンチン リュー，
ユエハン チアン，
リアンシャン タオ，
ジファン ウェン，
ジー シ，
ヤオリン ワン，
Original Assignee
インベンティスバイオ カンパニー リミテッド
インベンティスバイオ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インベンティスバイオ カンパニー リミテッド, インベンティスバイオ リミテッド ライアビリティ カンパニー filed Critical インベンティスバイオ カンパニー リミテッド
Publication of JP2023540228A publication Critical patent/JP2023540228A/ja
Publication of JP2023540228A5 publication Critical patent/JP2023540228A5/ja
Publication of JPWO2022042630A5 publication Critical patent/JPWO2022042630A5/ja
Application granted granted Critical
Publication of JP7837952B2 publication Critical patent/JP7837952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023513401A 2020-08-26 2021-08-26 ヘテロアリール基化合物、その製造方法および使用 Active JP7837952B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/111302 2020-08-26
CN2020111302 2020-08-26
CN2021075781 2021-02-07
CNPCT/CN2021/075781 2021-02-07
PCT/CN2021/114676 WO2022042630A1 (en) 2020-08-26 2021-08-26 Heteroaryl compounds, preparation methods and uses thereof

Publications (4)

Publication Number Publication Date
JP2023540228A JP2023540228A (ja) 2023-09-22
JP2023540228A5 JP2023540228A5 (https=) 2024-08-28
JPWO2022042630A5 JPWO2022042630A5 (https=) 2024-08-28
JP7837952B2 true JP7837952B2 (ja) 2026-03-31

Family

ID=80354683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513401A Active JP7837952B2 (ja) 2020-08-26 2021-08-26 ヘテロアリール基化合物、その製造方法および使用

Country Status (5)

Country Link
US (1) US20230357233A1 (https=)
EP (1) EP4204412A4 (https=)
JP (1) JP7837952B2 (https=)
CN (1) CN115968286A (https=)
WO (1) WO2022042630A1 (https=)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
EP4182313A4 (en) * 2020-07-16 2024-10-09 Mirati Therapeutics, Inc. KRAS-G12D INHIBITORS
WO2022170999A1 (zh) * 2021-02-09 2022-08-18 南京明德新药研发有限公司 吡啶[4，3-d]嘧啶类化合物
CN116964058A (zh) * 2021-03-15 2023-10-27 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CN115109078A (zh) * 2021-03-22 2022-09-27 苏州泽璟生物制药股份有限公司 嘧啶并吡啶类抑制剂及其制备方法和应用
CN115141215B (zh) * 2021-03-30 2023-09-15 上海德琪医药科技有限公司 Kras g12d蛋白抑制剂和其用途
WO2022206724A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
WO2022214102A1 (zh) * 2021-04-09 2022-10-13 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
CN115197245A (zh) * 2021-04-09 2022-10-18 上海拓界生物医药科技有限公司 一种Kras抑制剂及其制备方法
WO2022217042A1 (en) * 2021-04-09 2022-10-13 Ikena Oncology, Inc. Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
WO2022227987A1 (zh) * 2021-04-28 2022-11-03 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
CN117222650A (zh) * 2021-04-30 2023-12-12 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物，其制法与医药上的用途
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022236578A1 (en) * 2021-05-10 2022-11-17 Nikang Therapeutics, Inc. Exocyclic amino quinazoline derivatives as kras inhibitors
WO2022247760A1 (zh) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
WO2022248885A2 (en) * 2021-05-28 2022-12-01 Redx Pharma Plc. Compounds
WO2022262686A1 (en) * 2021-06-13 2022-12-22 Jingrui Biopharma Co., Ltd. Kras g12d inhibitors
WO2022266015A1 (en) * 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
WO2023274324A1 (zh) * 2021-06-30 2023-01-05 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法、中间体及应用
WO2023284881A1 (en) * 2021-07-16 2023-01-19 Silexon Ai Technology Co., Ltd. Heterocyclic compounds useful as kras g12d inhibitors
CN117157292A (zh) * 2021-07-16 2023-12-01 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
CN116669740A (zh) * 2021-08-16 2023-08-29 华润医药研究院（深圳）有限公司 嘧啶并吡啶类化合物及其制备方法和医药用途
TW202328124A (zh) * 2021-08-18 2023-07-16 大陸商北京加科思新藥研發有限公司 1,4-氧雜氮雜環庚烷衍生物及其用途
WO2023020521A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Pyridine fused pyrimidine derivatives and use thereof
WO2023020523A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Bicyclic derivatives and use thereof
CN116284055B (zh) * 2021-09-10 2025-09-23 润佳（苏州）医药科技有限公司 一种kras抑制剂及其用途
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
EP4417606A4 (en) * 2021-10-15 2025-10-22 Sunshine Lake Pharma Co Ltd NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
TW202334138A (zh) 2021-11-05 2023-09-01 美商新領域醫藥公司 癌症治療方法
CN117940436A (zh) * 2021-12-02 2024-04-26 上海和誉生物医药科技有限公司 一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用
CN116217591A (zh) * 2021-12-02 2023-06-06 思路迪生物医药(上海)有限公司 一类作为kras g12d突变抑制剂的吡啶并嘧啶类衍生物
WO2023103523A1 (zh) * 2021-12-09 2023-06-15 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
EP4452974A4 (en) * 2021-12-21 2025-11-19 Bridgene Biosciences Inc RAS ONCOPROTEIN INHIBITORS
WO2023134465A1 (zh) * 2022-01-11 2023-07-20 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法、中间体及应用
CN118556063A (zh) * 2022-01-21 2024-08-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
WO2023143312A1 (zh) * 2022-01-28 2023-08-03 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法及应用
AU2023218370B2 (en) 2022-02-09 2024-11-28 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN117659049A (zh) * 2022-08-23 2024-03-08 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
CN119317628A (zh) * 2022-03-22 2025-01-14 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
CN114573438A (zh) * 2022-03-31 2022-06-03 上海应用技术大学 一种单氟氯/溴代丙酮类化合物及其制备方法
CN119365459A (zh) * 2022-04-11 2025-01-24 杭州英创医药科技有限公司 作为kras g12d抑制剂的多环化合物
CN116891488B (zh) * 2022-04-11 2025-12-12 成都海博为药业有限公司 稠环化合物、包含其的药物组合物及应用
WO2023198191A1 (zh) * 2022-04-15 2023-10-19 杭州多域生物技术有限公司 一种六元并六元化合物、制备方法、药物组合物和应用
IL317601A (en) 2022-05-25 2025-02-01 Quanta Therapeutics Inc Pyrimidine-based modulators and their uses
WO2023246903A1 (zh) * 2022-06-24 2023-12-28 暨南大学 含硒杂环类化合物及其药用组合物和应用
WO2024008178A1 (zh) * 2022-07-08 2024-01-11 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
WO2024012519A1 (zh) * 2022-07-13 2024-01-18 北京华森英诺生物科技有限公司 Pan-kras抑制剂
KR20250042155A (ko) 2022-07-27 2025-03-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 축합 고리계 화합물, 이의 제조 방법 및 이의 의학적 응용
CA3261681A1 (en) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
CN120018863A (zh) * 2022-08-24 2025-05-16 珃诺生物医药科技(杭州)有限公司 用于调节kras(g12d)的方法和组合物
WO2024045066A1 (en) * 2022-08-31 2024-03-07 Nikang Therapeutics, Inc. Alkylidene carbamate as kras inhibitors
KR20250057027A (ko) * 2022-09-07 2025-04-28 브리스톨-마이어스 스큅 컴퍼니 Kras g12d 억제제
WO2024051721A1 (en) * 2022-09-07 2024-03-14 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024051852A1 (zh) * 2022-09-09 2024-03-14 上海翰森生物医药科技有限公司 含嘧啶多环类生物抑制剂、其制备方法和应用
CN120500484A (zh) * 2022-09-09 2025-08-15 珃诺生物医药科技(杭州)有限公司 作为用于治疗癌症的kras（g12d）突变型癌蛋白抑制剂的4-(3,8-二氮杂双环[3.2.1]辛烷-3-基)-7-萘-吡啶并[4,3-d]嘧啶衍生物
CN119855815A (zh) * 2022-09-21 2025-04-18 甘李药业股份有限公司 一种kras突变蛋白抑制剂、及其制备方法和应用
CN117800976A (zh) * 2022-09-30 2024-04-02 上海凌达生物医药有限公司 一类含氮杂环类化合物、制备方法和用途
CN117886833A (zh) * 2022-10-13 2024-04-16 广东东阳光药业股份有限公司 一种嘧啶并吡啶化合物、其药物组合物及其用途
JP2026504244A (ja) 2022-11-09 2026-02-04 レヴォリューション・メディスンズ，インコーポレイテッド 化合物、複合体、ならびにそれらの調製方法及びそれらの使用方法
WO2024234360A1 (en) * 2023-05-18 2024-11-21 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
WO2024192424A1 (en) 2023-03-15 2024-09-19 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2024215862A2 (en) * 2023-04-12 2024-10-17 Board Of Regents, The University Of Texas System Heterocyclic compounds as nras inhibitors
WO2024213122A1 (zh) * 2023-04-14 2024-10-17 广东东阳光药业股份有限公司 Kras抑制剂化合物、其药物组合物及其用途
WO2025002302A1 (zh) * 2023-06-28 2025-01-02 广东东阳光药业股份有限公司 嘧啶并吡啶化合物、其药物组合物及其用途
AU2024320375A1 (en) * 2023-08-08 2026-02-19 Lawrence Livermore National Security, Llc Fused pyridines for the treatment of cancer and other indications
TW202523324A (zh) * 2023-10-08 2025-06-16 大陸商成都海博為藥業有限公司 一種稠環化合物及應用
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024357850A1 (en) 2023-10-09 2026-04-23 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
CN117683052A (zh) * 2023-12-07 2024-03-12 上海相辉医药科技有限公司 一种kras g12d抑制剂mrtx1133的制备方法
WO2025123318A1 (en) * 2023-12-15 2025-06-19 Shanghai Blueray Biopharma Co., Ltd. TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060404A1 (en) 2005-11-22 2007-05-31 Kudos Pharmaceuticals Limited PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2020113071A1 (en) 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2021526132A (ja) 2018-06-12 2021-09-30 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
JP2022546043A (ja) 2019-08-29 2022-11-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
JP2023533464A (ja) 2020-06-25 2023-08-03 トルレモ・セラピューティクス・アクチェンゲゼルシャフト がんを治療するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＫＲＡＳ阻害剤の組合せ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060404A1 (en) 2005-11-22 2007-05-31 Kudos Pharmaceuticals Limited PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
JP2021526132A (ja) 2018-06-12 2021-09-30 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020113071A1 (en) 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2022546043A (ja) 2019-08-29 2022-11-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
JP2023533464A (ja) 2020-06-25 2023-08-03 トルレモ・セラピューティクス・アクチェンゲゼルシャフト がんを治療するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＫＲＡＳ阻害剤の組合せ

Also Published As

Publication number Publication date
EP4204412A1 (en) 2023-07-05
CN115968286A (zh) 2023-04-14
WO2022042630A1 (en) 2022-03-03
US20230357233A1 (en) 2023-11-09
JP2023540228A (ja) 2023-09-22
EP4204412A4 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
JP7837952B2 (ja) ヘテロアリール基化合物、その製造方法および使用
JP2023531269A (ja) キナゾリン化合物、その製造方法および用途
KR102944305B1 (ko) 헤테로 고리 화합물, 이의 제조 방법 및 용도
CN117500799A (zh) 作为kras g12d抑制剂的取代的稠合吖嗪
ES2585009T3 (es) Derivados de 3,4-dihidro-2H-pirido[1,2-a]pirazina-1,6-diona sustituidos útiles para el tratamiento de (inter alia) enfermedad de Alzheimer
RU2666349C2 (ru) Новое конденсированное пиримидиновое соединение или его соль
KR20220012248A (ko) 퀴나졸린 화합물 및 이의 의약품에서의 응용
JP2024532845A (ja) ピリダジノンまたはピリジノン化合物、その製造方法および用途
JP7134173B2 (ja) Ｅｐ３００／ｃｒｅｂｂｐ阻害剤
US10202389B2 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
AU2020388114A1 (en) Macrocyclic indole derivatives as MCL-1 inhibitors
CA3168355A1 (en) Macrocyclic indole derivatives as inhibitors of mcl-1
US20250122183A1 (en) Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives
HK40085726A (en) Quinazoline compounds, preparation methods and uses thereof
EP4531849A1 (en) Heterocyclic pad4 inhibitors
CN117447520A (zh) 一种苯并环取代嘧啶类化合物及其应用
HK1238244A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240820

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260318

R150 Certificate of patent or registration of utility model

Ref document number: 7837952

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150